Merck KGaA pays 130% premium for Silence RNAi asset
Merck KGaA is spending $1.3 billion to buy Silence Therapeutics, a 130% premium that marks the second-highest markup on a major biotech deal this year
Incyte
Every Fin-node story mentioning Incyte — 1 story, newest first.
Incyte · 1 story